[001] The subject matter described herein in general relates to health compositions, and in particular, relates to the herbal pharmaceuticals. BACKGROUND OF INVENTION
[002] Modern human lifestyle has led to rampant increase in diseases such as diabetes. Associated complications such as obesity are also known to be a major health-risk. Diabetes is recognized as a global burden by International Diabetes Federation and often characterized by a group of heterogeneous disorders with the common elements of hyperglycemia and glucose intolerance, caused due to insulin deficiency, impaired effectiveness of insulin action, and/or both. Post prandial hyperglycemia is a long-identified symptom of Type 2 diabetes. To address the same, International Diabetes Federation has come up with newer targets such as alpha glucosidase inhibitors (decrease rate of carbohydrate absorption from the gut), GLP-1 (glucagon-like peptide) mimetics and DPP-4 (dipeptidyl peptidase 4) inhibitors (IDF Clinical Guidelines Task Force. Global guideline for Type-2 diabetes. Brussels: International Diabetes Federation, 2005 and 2012). [003] In an associated aspect, the increased accumulation of free radicals has been implicated in various diseases pertaining to inflammatory conditions, peroxidation of membrane lipids, nucleic acid damage, and the oxidation of sulfhydryl and other susceptible groups in proteins (Middleton et al. 2000. The Effects of Plant Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer. Pharmacol Rev 52:673-751). This elucidates the significance of reducing oxidative damage via use of antioxidant compounds. [004] Synthetic compositions have been used over the years, however, these suffer from numerous drawbacks such as adverse side-effects. In the recent years, owing to bio-compatibility concerns, compositions derived from natural sources, have grown in prominence. Attempts have been made to use herbal actives such as quercetin for obtaining compositions that may benefit health of consumers (US7745486B2). Flavonoids such as quercetin have been recently explored for their bio-active role. US20170087125 reveals a composition comprising quercetin, for treatment of cancer.

SUMMARY OF THE INVENTION
[005] In an aspect of the present invention, there is provided a herbal composition
comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is in a
range of 1:0.5 to 1:7.
[006] In another aspect of the present invention, there is provided a process for
preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein
quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7, said process comprising
steps of: a) obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and
rutin to obtain the composition.
[007] These and other features, aspects, and advantages of the present subject
matter will be better understood with reference to the following description and
appended claims. This summary is provided to introduce a selection of concepts in
a simplified form. This summary is not intended to identify key features or
essential features of the claimed subject matter, nor is it intended to be used to limit
the scope of the claimed subject matter.
BRIEF DESCRIPTION OF THE DRAWINGS
[008] The detailed description is described with reference to the accompanying
figures. The same numbers are used throughout the drawings to reference like
features and components.
[009] Figure 1 illustrates the effect of varying concentrations of quercetin on
alpha glucosidase inhibition, in accordance with an implementation of the present
subject matter.
[0010] Figure 2 illustrates the effect of varying concentrations of rutin on alpha
glucosidase inhibition, in accordance with an implementation of the present subject
matter.
[0011] Figure 3 illustrates the effect of combination of quercetin and rutin on alpha
glucosidase inhibition, in accordance with an implementation of the present subject
matter.
[0012] Figure 4 illustrates the effect of combination of quercetin and rutin on
cellular ROS inhibition, in accordance with an implementation of the present
subject matter.

DETAILED DESCRIPTION OF THE INVENTION
[0013] Those skilled in the art will be aware that the present disclosure is subject to
variations and modifications other than those specifically described. It is to be
understood that the present disclosure includes all such variations and
modifications. The disclosure also includes all such steps, features, compositions,
and compounds referred to or indicated in this specification, individually or
collectively, and any and all combinations of any or more of such steps or features.
Definitions
[0014] For convenience, before further description of the present disclosure,
certain terms employed in the specification, and examples are delineated here.
These definitions should be read in the light of the remainder of the disclosure and
understood as by a person of skill in the art. The terms used herein have the
meanings recognized and known to those of skill in the art, however, for
convenience and completeness, particular terms and their meanings are set forth
below.
[0015] The articles "a", "an" and "the" are used to refer to one or to more than one
(i.e., to at least one) of the grammatical object of the article.
[0016] The terms "comprise" and "comprising" are used in the inclusive, open
sense, meaning that additional elements may be included. It is not intended to be
construed as "consists of only".
[0017] Throughout this specification, unless the context requires otherwise the
word "comprise", and variations such as "comprises" and "comprising", will be
understood to imply the inclusion of a stated element or step or group of element or
steps but not the exclusion of any other element or step or group of element or
steps.
[0018] The term "including" is used to mean "including but not limited to".
"Including" and "including but not limited to" are used interchangeably.
[0019] Ratios, concentrations, amounts, and other numerical data may be presented
herein in a range format. It is to be understood that such range format is used
merely for convenience and brevity and should be interpreted flexibly to include

not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a concentration ranges of about 25-90 uM should be interpreted to include not only the explicitly recited limits of about 25 uM to about 90 uM, but also to include sub-ranges, such as 25-80 uM, 28-90 uM, and so forth, as well as individual amounts, including fractional amounts, within the specified ranges, such as 25.5 uM, and 89.5 uM, for example.
[0020] The term "at least one" is used to mean one or more and thus includes individual components as well as mixtures/combinations.
[0021] A composition comprising "synergistic activity" or a "synergistic composition" is a combination of compounds which exhibits increased biological or functional activity as a non-linear multiple of the biological or functional activity of the individual compounds. In other words, the combined biological or functional activity of two or more compounds being tested is significantly greater than the expected result based on independent effects of the compounds when tested separately. Synergy may be apparent only at some ranges or weight percentages.
[0022] Carriers are substances that serve as mechanisms to improve the delivery and the effectiveness of drugs.
[0023] The term "reactive oxygen species" (ROS) collectively denotes oxygen-centered radicals such as superoxide and hydroxyl as well as nonradical species derived from oxygen, such as hydrogen peroxide, singlet oxygen, and hypochlorous acid.
[0024] Flavonoids are a class of phytochemicals characterized by a phenylbenzo(v)pyrone-derived structure consisting of two benzene rings linked by a heterocyclic pyran or pyrone ring. Flavonoids comprise various flavones, chalcones, flavanols, anthocyanidins. Quercetin and rutin are two such flavonoids wherein, quercetin is the aglycone form and rutin (glycone) contains a rutinose sugar moiety at the 3-position of the unsaturated C-ring. Quercetin is naturally present in tea, onion, apple and other fruits, vegetables, grains.

[0025] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. [0026] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein. [0027] As mentioned previously, there is a need in the art to provide a suitable herbal composition that is capable of effectively inhibiting the production of reactive oxygen species (ROS) as well as inhibiting alpha glucosidase activity. The present disclosure relates to the efficacy of two phytochemicals - quercetin and rutin alone as well as in combination. The results show that the combination is synergistic in the weight ratio range of 1:1 to 1:7 for alpha glucosidase inhibition. The composition was also found to be inhibit ROS production at weight ratio range of 1:0.67 to 1:7.
[0028] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7. In another embodiment of the present disclosure, quercetin to rutin weight ratio is in a range of 1:0.5 to 1:6.5. [0029] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7. In another embodiment of the present disclosure, quercetin to rutin weight ratio is in a range of 1:1.5 to 1:6.5. [0030] In an embodiment of the present disclosure, there is provided a herbal composition as described herein, wherein quercetin to rutin weight ratio is 1:2. [0031] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is 1:0.67.

[0032] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is 1:2.
[0033] In an embodiment of the present disclosure, there is provided a herbal composition as described herein, wherein quercetin to rutin weight ratio is 1:6. [0034] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is 1:6.
[0035] In an embodiment of the present disclosure, there is provided a herbal composition as described herein, wherein the composition further comprises at least one carrier selected from the group consisting of dimethylsulfoxide, water, and combinations thereof. In another embodiment of the present disclosure, the at least one carrier is dimethylsulfoxide (DMSO).
[0036] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; b) rutin; and c) at least one carrier selected from the group consisting of dimethylsulfoxide, water, and combinations thereof, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7. [0037] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; b) rutin; and c) at least one carrier selected from the group consisting of dimethylsulfoxide, water, and combinations thereof, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7. [0038] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin having a concentration in a range of 25 - 90 uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one carrier, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7. In another embodiment of the present disclosure, the herbal composition comprises: a) quercetin having a concentration in a range of 28 - 80 uM; b) rutin having a concentration in a range of 122 - 220 uM; and c) at least one carrier. In yet another embodiment of the present disclosure, the herbal composition comprises: a) quercetin having a concentration in a range of 29 - 70 uM; b) rutin having a concentration in a range of 123 - 190 uM; and c) at least one carrier.

[0039] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin having a concentration in a range of 25 - 90
uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one
carrier, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7.
[0040] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin having a concentration in a range of 25 - 90
uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one
carrier, wherein quercetin to rutin weight ratio is 1:0.67.
[0041] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin having a concentration in a range of 25 - 90
uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one
carrier, wherein quercetin to rutin weight ratio is 1:2.
[0042] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin having a concentration in a range of 25 - 90
uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one
carrier, wherein quercetin to rutin weight ratio is 1:6.
[0043] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin having a concentration in a range of 25 - 90
uM; b) rutin having a concentration in a range of 120 - 249 uM; and c) at least one
carrier, wherein quercetin to rutin weight ratio is 1:6 or 1:2.
[0044] In an embodiment of the present disclosure, there is provided a herbal
composition as described herein, wherein the composition further comprises at
least one excipient selected from the group consisting of fillers, preservatives,
bulking agents, colouring agents, flavouring agents, emulsifying agents, and
combinations thereof. In another embodiment of the present disclosure said
excipients may be selected from known chemicals in the art.
[0045] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; b) rutin; and c) at least one excipient
selected from the group consisting of fillers, preservatives, bulking agents,
colouring agents, flavouring agents, emulsifying agents, and combinations thereof,
wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7.

[0046] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; b) rutin; and c) at least one excipient selected from the group consisting of fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7. [0047] In an embodiment of the present disclosure, there is provided a herbal composition comprising: a) quercetin; b) rutin; and c) at least one excipient selected from the group consisting of fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof, wherein quercetin to rutin weight ratio is 1:2.
[0048] In an embodiment of the present invention, there is provided a herbal composition comprising: a) quercetin; b) rutin; and c) at least one excipient selected from the group consisting of fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof, wherein quercetin to rutin weight ratio is 1:6.
[0049] In an embodiment of the present invention, there is provided a herbal composition comprising: a) quercetin; b) rutin; c) at least one carrier selected from the group consisting of dimethylsulfoxide, water; and d) at least one excipient selected from the group consisting of fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof, and combinations thereof, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7.
[0050] In an embodiment of the present invention, there is provided a herbal composition comprising: a) quercetin; b) rutin; c) at least one carrier selected from the group consisting of dimethylsulfoxide, water; and d) at least one excipient selected from the group consisting of fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof, and combinations thereof, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7.

[0051] In an embodiment of the present disclosure, there is provided a herbal
composition as described herein, wherein the composition effectively inhibits
production of reactive oxygen species.
[0052] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is in a range of 1:0.5 to 1:7, and the composition effectively inhibits
production of reactive oxygen species.
[0053] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is in a range of 1:1 to 1:7, and the composition effectively inhibits
production of reactive oxygen species.
[0054] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is 1:0.67, and the composition effectively inhibits production of
reactive oxygen species.
[0055] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is 1:2, and the composition effectively inhibits production of reactive
oxygen species.
[0056] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is 1:6, and the composition effectively inhibits production of reactive
oxygen species.
[0057] In an embodiment of the present disclosure, there is provided a herbal
composition as described herein, wherein the composition synergistically inhibits
alpha glucosidase activity.
[0058] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is in a range of 1:0.5 to 1:7, and the composition synergistically
inhibits alpha glucosidase activity.

[0059] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is in a range of 1:1 to 1:7, and the composition synergistically inhibits
alpha glucosidase activity.
[0060] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is 1:2, and the composition synergistically inhibits alpha glucosidase
activity.
[0061] In an embodiment of the present disclosure, there is provided a herbal
composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin
weight ratio is 1:6, and the composition synergistically inhibits alpha glucosidase
activity.
[0062] In an embodiment of the present disclosure, there is provided a process for
preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein
quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7, said process comprising
steps of: a) obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and
rutin to obtain the composition.
[0063] In an embodiment of the present disclosure, there is provided a process for
preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein
quercetin to rutin weight ratio is in a range of 1:1 to 1:7, said process comprising
steps of: a) obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and
rutin to obtain the composition.
[0064] In an embodiment of the present disclosure, there is provided a process for
preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein
quercetin to rutin weight ratio is 1:0.67, said process comprising the steps of: a)
obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and rutin to
obtain the composition.
[0065] In an embodiment of the present disclosure, there is provided a process for
preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein
quercetin to rutin weight ratio is 1:2, said process comprising the steps of: a)

obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and rutin to obtain the composition.
[0066] In an embodiment of the present disclosure, there is provided a process for preparing the herbal composition comprising: a) quercetin; and b) rutin, wherein quercetin to rutin weight ratio is 1:6, said process comprising the steps of: a) obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and rutin to obtain the composition.
[0067] In an embodiment of the present disclosure, there is provided a process for preparing the herbal composition comprising: a) quercetin; b) rutin; and c) at least one carrier, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7, said process comprising steps of: a) obtaining quercetin; b) obtaining rutin; c) obtaining at least one carrier; and c) contacting quercetin and rutin with at least one carrier to obtain the composition.
[0068] In an embodiment of the present disclosure, there is provided a process for preparing the herbal composition comprising: a) quercetin; b) rutin; and c) at least one excipient, wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7, said process comprising steps of: a) obtaining quercetin; b) obtaining rutin; c) obtaining at least one excipient; and c) contacting quercetin and rutin with at least one excipient to obtain the composition.
[0069] In an embodiment of the present disclosure, there is provided a process for preparing the herbal composition comprising: a) quercetin; b) rutin; and c) at least one carrier, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7, said process comprising steps of: a) obtaining quercetin; b) obtaining rutin; c) obtaining at least one carrier; and c) contacting quercetin and rutin with at least one carrier to obtain the composition.
[0070] In an embodiment of the present disclosure, there is provided a process for preparing the herbal composition comprising: a) quercetin; b) rutin; and c) at least one excipient, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7, said process comprising steps of: a) obtaining quercetin; b) obtaining rutin; c) obtaining at least one excipient; and c) contacting quercetin and rutin with at least one excipient to obtain the composition.

[0071] In an embodiment of the present disclosure, there is provided a herbal composition as described herein, wherein the composition is dispensed in the form of beverages (liquid as well as powders), juice, dairy formats, nutraceuticals. In another embodiment of the present disclosure, the composition may be dispensed as part of dietary or food supplements. Other known forms may be construed to be part of the present disclosure. EXAMPLES
[0072] The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein. It is to be understood that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may apply. [0073] Dietary carbohydrate absorption is an important factor involved in regulating levels of carbohydrate digestion and available glucose for absorption. An impairment at this level would in turn lead to an imbalance in fat mass and energy homeostasis. This may further lead to metabolic disorder risk factors (Impact of Dietary Polyphenols on Carbohydrate Metabolism, Hanhineva et al, Int. J. Mol. Sci. 2010, 11, 1365-1402). Glucosidase enzymes are involved in several biological processes such as the intestinal digestion, the biosynthesis of glycoproteins and the lysosomal catabolism of the glycoconjugates. Intestinal alpha-glucosidases are involved in the final step of the carbohydrate digestion which convert these molecules into monosaccharides for absorption through the intestine. This makes alpha glucosidases an important biological target for management of carbohydrate absorption and in turn glucose levels from dietary sources. As a result of the catalysis by alpha-glucosidase enzyme in the final step in the digestive process of carbohydrates, inhibitors of this enzyme can reduce the

uptake of dietary carbohydrates and suppress postprandial hyperglycemia (Hashimoto Y et al, Bioorg. Med. Chem. Lett., 2000, 10, 1081). Consumption of dietary carbohydrates is known to impact blood sugar levels. It is thus useful to explore those polysaccharides which can add body to the product without impacting increase in blood sugar levels. This can be evaluated in vitro by testing the effect of such ingredients on alpha glucosidase inhibition. Furthermore, reactive oxygen species (ROS) are well-known for their detrimental effect on biological systems. As described previously, there is a need for herbal compositions that are able to provide suitable inhibitory activity against alpha glucosidase enzyme along with inhibition of ROS. Materials and methods
[0074] Quercetin and rutin were procured from Sigma. The samples were suitably dissolved in appropriate concentrations (listed below in Table 1) in at least one carrier (dimethylsulfoxide) prior to performing the below mentioned tests. EXAMPLE 1
Effect of quercetin and rutin on alpha glucosidase inhibition [0075] Alpha glucosidase as mentioned previously, is an established marker for identifying diabetic conditions. The enhancement in alpha glucosidase activity leads to enhanced levels of blood sugar. Hence, compositions that can inhibit alpha glucosidase activity are sought after.
[0076] The alpha glucosidase assay was carried out with a total reaction volume of 200uL comprising assay buffer, substrate, inhibitor and enzyme. 0.1M phosphate buffer at a pH 7 is used as the assay buffer as well as the solvent for enzyme and substrate solutions. The assay components are added in their respective volumes and the reaction was started by adding the enzyme. The reaction was carried out at 37°C for one hour with the absorbance readings being measured every one minute. The assay was based on the action of alpha-glucosidase enzyme which acts on alpha-1,4-glucosidie bonds. The substrate used in the assay was para-nitrophenol tagged alpha-D-glucopyranoside. The enzyme acts on the substrate and p-nitrophenol is released, absorbance of which was measured colorimetrically at 410nm. Enzyme preparation was carried out using

500mg of rat intestinal acetone powder and to it lOmL of ice cold assay buffer was added. The solution was vortexed gently and allowed to stand in ice for 2minutes. The mix was then centrifuged at 8000rpm for 8 minutes. The supernatant was transferred to a fresh tube and the pellet discarded. The supernatant aliquots were used as the enzyme solution. The above procedure was carried out at 4°C and the enzyme solutions were stored at -20°C. Percentage inhibition was calculated as, % Inhibition = (Absorbance control - Absorbance Test)/ Absorbance control] x 100 (Refer Fig 1 to 3).
Identification of optimal effective concentrations of quercetin and rutin [0077] Figure 1, indicates the effect of varying concentrations of quercetin on alpha glucosidase inhibition. The assay was carried out using the protocol as described herein-above. Concentrations showing maximum efficacy were selected. Even though the results indicated in Figures 1 and 2 reveal highest efficacy for 250 uM of both rutin and quercetin, other factors were taken into account while selecting the concentrations to be further pursued. In case of rutin, higher concentration than 250 uM, was found to interfere with the assay readouts. Similarly, quercetin was found to be incompatible above 125 uM. Hence, quercetin was tested up to a maximum of 125 uM and rutin was tested up to a maximum of 250 uM.
Effect of composition (quercetin + rutin) on alpha glucosidase inhibition [0078] The combinatorial effect of quercetin and rutin was evaluated at the ratios as indicated in Table 1 below. Table 1- Combinations of quercetin and rutin and respective ratios.

[0079] The result can be observed from Figure 3. Enhanced inhibition of alpha glucosidase by the composition comprising both quercetin and rutin is clearly observed. Quercetin and rutin were combined in various weight ratios. The individual contribution towards inhibition for both rutin and quercetin were estimated by extrapolation of above-mentioned dose curve data (Figures 1 and 2). Table 2- Compilation of alpha glucosidase inhibition data
[0080] As mentioned in Table 2, the weight by weight ratios of 1:2 and 1:6 showed surprising synergistic inhibition of alpha glucosidase, with 29% and 32% inhibition, which was found to be significantly higher than the additive (calculated) values of 22% and 24%, respectively. As can be appreciated from Figures 1, 2 and 3, the synergistic inhibition of alpha glucosidase using a composition comprising quercetin and rutin, having a weight ratio in the range of 1:1 to 1:7 was both unexpected and required significant experimental effort. Example 2
Effect of combination of quercetin and rutin on cellular ROS inhibition [0081] As previously mentioned, reactive oxygen species (ROS) cause significant harm to cellular systems and their concentrations is found to be enhanced under stress or diseased conditions. A composition that can inhibit the production ROS can hence, be quite useful.
[0082] ROS was measured in HepG2 cells using 2',7' -dichlorofluorescein diacetate (DCFDA) dye. DCFDA, is a fluorogenic dye that measures hydroxyl, peroxyl and other ROS activity within the cell. After diffusion in to the cell,

DCFDA is deacetylated by cellular esterases to a non-fluorescent compound, which is later oxidized by ROS into 2', T -dichlorofluorescin (DCF). HepG2 cells were seeded in 96 well black clear bottom plate and incubated at 37°C and 5% CO2. DMEM medium with 10% FBS and 1% antibiotics was used for culturing. After overnight incubation, the cells were treated in serum-free medium with ingredients at the respective ratios (as shown in Table 1) and maximum individual concentration of 125uM and 250uM for quercetin and rutin respectively. The treated cells were incubated for 6 hours. After incubation, cells were washed with IX PBS and stained with 25uM DCFDA for 30 minutes at 37°C. After this step, cells were washed once with IX PBS. Fluorescence was measured with excitation wavelength at 485 nm and emission wavelength at 535 nm in a plate reader. Percentage inhibition was calculated as, % inhibition = [(Absorbance controi -Absorbance Test)/ Absorbance control] X 100 (Refer Figure 4).
[0083] From Figure 4, it can be identified that in addition to synergistic inhibition of alpha glucosidase, the composition of quercetin and rutin having weight ratios of 1:0.67, 1:2 and 1:6 as described herein, were able to effectively inhibit the production of ROS. Thus, the inhibition of ROS using a composition comprising quercetin and rutin, having a weight ratio in the range of 1:0.5 to 1:7 was both unexpected and required significant experimental effort. This finding also suggests a role of glycosylation in antioxidant and dietary carbohydrate absorption inhibition properties of glycones and aglycones.
Advantages of the present disclosure:
[0084] The present disclosure reveals a composition comprising herbal ingredients that is effective against inhibition of alpha glucosidase. The composition comprising quercetin and rutin, having a weight ratio in the range of 1:1 - 1:7, was found to synergistically inhibit alpha glucosidase. The combination having the ratio range of 1:0.5 to 1:7 was also to effectively inhibit production of reactive oxygen species (ROS). The composition can be easily adapted into useful commercial formats such as beverages, juices, dairy formats, nutraceuticals, among others.

I/We Claim:
1. A herbal composition comprising:
a) quercetin; and
b) rutin,
wherein quercetin to rutin weight ratio is in a range of 1:0.5 to 1:7.
2. The herbal composition as claimed in claim 1, wherein quercetin to rutin weight ratio is in a range of 1:1 to 1:7.
3. The herbal composition as claimed in claim 1, wherein quercetin to rutin weight ratio is 1:2.
4. The herbal composition as claimed in claim 1, wherein quercetin to rutin weight ratio is 1:6.
5. The herbal composition as claimed in claim 1, wherein the composition further comprises at least one carrier selected from the group consisting of dimethylsulfoxide, water, and combinations thereof.
6. The herbal composition as claimed in claim 5, wherein the composition comprises:

a) quercetin having a concentration in a range of 25 - 90 uM;
b) rutin having a concentration in a range of 120 - 249 uM; and
c) at least one carrier.

7. The herbal composition as claimed in any one of the claims 1-6, wherein the composition further comprises at least one excipient selected from fillers, preservatives, bulking agents, colouring agents, flavouring agents, emulsifying agents, and combinations thereof
8. The herbal composition as claimed in any one of the claims 1-7, wherein the composition effectively inhibits production of reactive oxygen species.
9. The herbal composition as claimed in any one of the claims 1-8, wherein
the composition synergistically inhibits alpha glucosidase activity.

10. A process for preparing the herbal composition as claimed in claim 1, said process comprising the steps of: a) obtaining quercetin; b) obtaining rutin; and c) contacting quercetin and rutin to obtain the composition.